share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K:重大事件
美股SEC公告 ·  10/04 04:32

Moomoo AI 已提取核心信息

Aditxt, Inc., a biotech company, has filed a Form 8-K with the SEC, reporting several significant corporate developments. On October 1, 2024, Aditxt announced an amendment to its merger agreement with Evofem Biosciences, Inc., which included changes to the schedule and amounts of equity investments in Evofem. The third equity investment was adjusted to $720,000 and the fourth to $2.28 million, with the third investment's date extended to October 2, 2024. Additionally, Aditxt completed a reverse stock split at a ratio of 1-for-40, effective October 1, 2024, with the company's common stock trading on a split-adjusted basis from October 2, 2024. The reverse stock split consolidated every 40 shares of issued and outstanding common stock into one share, with a proportionate adjustment to the exercise price and number...Show More
Aditxt, Inc., a biotech company, has filed a Form 8-K with the SEC, reporting several significant corporate developments. On October 1, 2024, Aditxt announced an amendment to its merger agreement with Evofem Biosciences, Inc., which included changes to the schedule and amounts of equity investments in Evofem. The third equity investment was adjusted to $720,000 and the fourth to $2.28 million, with the third investment's date extended to October 2, 2024. Additionally, Aditxt completed a reverse stock split at a ratio of 1-for-40, effective October 1, 2024, with the company's common stock trading on a split-adjusted basis from October 2, 2024. The reverse stock split consolidated every 40 shares of issued and outstanding common stock into one share, with a proportionate adjustment to the exercise price and number of shares issuable for stock options, restricted stock units, and warrants. The company's common stock continues to trade on the Nasdaq under the symbol 'ADTX' with a new CUSIP number. These corporate actions follow a series of amendments to the merger agreement and securities purchase agreements with Evofem, as detailed in previous SEC filings by Aditxt.
生物技术公司Aditxt,Inc.已向证监会提交了8-k表格,报告了几项重大企业发展。2024年10月1日,Aditxt宣布对其与Evofem Biosciences,Inc.的合并协议进行了修订,包括对Evofem的股权投资时间表和金额的更改。第三笔股权投资调整为$720,000,第四笔为$228万,第三笔投资的日期延长至2024年10月2日。此外,Aditxt完成了1比40的股票逆向拆分,有效日期为2024年10月1日,公司的普通股从2024年10月2日起在拆分调整后交易。股票逆向拆分将每40股已发行和流通普通股合并为1股,对期权、限制性股票单位和认股权的行使价格和可发行股份数进行了比例调整。公司的普通股继续在纳斯达克交易,标的为“ADTX”,并获得了新的CUSIP编号。这些企业行动是对Aditxt此前提交的有关与Evofem的合并协议和证券购买协议的一系列修订的跟进,详情请参阅Aditxt之前向证监会提交的文件。
生物技术公司Aditxt,Inc.已向证监会提交了8-k表格,报告了几项重大企业发展。2024年10月1日,Aditxt宣布对其与Evofem Biosciences,Inc.的合并协议进行了修订,包括对Evofem的股权投资时间表和金额的更改。第三笔股权投资调整为$720,000,第四笔为$228万,第三笔投资的日期延长至2024年10月2日。此外,Aditxt完成了1比40的股票逆向拆分,有效日期为2024年10月1日,公司的普通股从2024年10月2日起在拆分调整后交易。股票逆向拆分将每40股已发行和流通普通股合并为1股,对期权、限制性股票单位和认股权的行使价格和可发行股份数进行了比例调整。公司的普通股继续在纳斯达克交易,标的为“ADTX”,并获得了新的CUSIP编号。这些企业行动是对Aditxt此前提交的有关与Evofem的合并协议和证券购买协议的一系列修订的跟进,详情请参阅Aditxt之前向证监会提交的文件。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息